(Q51678616)

9 April 2018

editorial

0 references

title

Everolimus and sunitinib: from mouse models to treatment of pancreatic neuroendocrine tumors. (English)

1 reference

9 April 2018

author

Dimitrios H. Roukos

series ordinal

2

1 reference

9 April 2018

author name string

Theodore Liakakos

series ordinal

1

1 reference

9 April 2018

language of work or name

English

0 references

publication date

1 September 2011

1 reference

9 April 2018

published in

Future Oncology

1 reference

9 April 2018

volume

7

1 reference

9 April 2018

issue

9

1 reference

9 April 2018

page(s)

1025-1029

1 reference

9 April 2018

Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial

cites work

1 reference

Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors

21 January 2018

1 reference

Molecular basis for sunitinib efficacy and future clinical development

21 January 2018

1 reference

Everolimus for advanced pancreatic neuroendocrine tumors.

21 January 2018

1 reference

Sunitinib malate for the treatment of pancreatic neuroendocrine tumors

21 January 2018

1 reference

Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors

21 January 2018

1 reference

One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States

21 January 2018

1 reference

[Neuroendocrine tumors of the duodenum and pancreas. Surgical strategy].

21 January 2018

1 reference

Neuroendocrine tumor epidemiology: contrasting Norway and North America.

21 January 2018

1 reference

Update on the treatment of neuroendocrine tumors

21 January 2018

1 reference

Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas

21 January 2018

1 reference

Lack of efficacy of streptozocin and doxorubicin in patients with advanced pancreatic endocrine tumors

21 January 2018

1 reference

Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group

21 January 2018

1 reference

Hallmarks of Cancer: The Next Generation

21 January 2018

1 reference

A perspective on cancer cell metastasis

21 January 2018

1 reference

Maximizing mouse cancer models

21 January 2018

1 reference

Heritable formation of pancreatic beta-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes

21 January 2018

1 reference

Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway

21 January 2018

1 reference

VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic beta cell carcinogenesis

21 January 2018

1 reference

A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer.

21 January 2018

1 reference

Activity of sunitinib in patients with advanced neuroendocrine tumors

21 January 2018

1 reference

Clinical outcome and long-term survival in 118 consecutive patients with neuroendocrine tumours of the pancreas

21 January 2018

1 reference

Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.2217/FON.11.88

1 reference

9 April 2018

1 reference

9 April 2018